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Prematurely born infants commonly develop respiratory dis-
tress syndrome (RDS) requiring some form of respiratory
support and potentially surfactant administration.1 Surfactant
administration improves outcomes. The standard approaches to
administer surfactant involve intubation and a period of inva-












► length of hospital stay
Abstract Background Less invasive surfactant administration (LISA) is the preferred mode of
surfactant administration for spontaneously breathing preterm babies supported by
noninvasive ventilation (NIV).
Objective The aim of this study was to determine whether LISA on the neonatal unit
or in the delivery suite was associated with reduced rates of bronchopulmonary
dysplasia (BPD) or the need for intubation, or lower durations of invasive ventilation
and length of hospital stay (LOS).
Methods A historical comparison was undertaken. Each “LISA” infant was matched
with two infants (controls) who did not receive LISA.
Results The 25 LISA infants had similar gestational ages and birth weights to the 50
controls (28 [25.6–31.7] weeks vs. 28.5 [25.4–31.9] weeks, p¼0.732; 1,120 (580–
1,810) g vs. 1,070 [540–1,869] g, p¼ 0.928), respectively. LISA infants had lower
requirement for intubation (52 vs. 90%, p< 0.001), shorter duration of invasive
ventilation (median 1 [0–35] days vs. 6 [0–62] days p¼0.001) and a lower incidence
of BPD (36 vs. 64%, p¼0.022). There were no significant differences in duration of NIV
(median 26 [3–225] vs. 23 [2–85] days, p¼0.831) or the total LOS (median 76 [24–
259] vs. 85 [27–221], p¼0.238).
Conclusion LISA on the neonatal unit or the delivery suite was associated with a lower
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Extubate (InSurE) technique.2 MV can cause damage to the
fragile preterm lungs leading to bronchopulmonary dyspla-
sia (BPD), so nowadays practitioners try to avoid intubation.
Indeed, the European Consensus Guidelines (20119) on the
management of RDS state that less invasive surfactant
administration (LISA) is the preferred mode of surfactant
administration for spontaneously breathing preterm babies
supported by continuous positive airway pressure (CPAP).3
During LISA, surfactant is delivered directly into the lungs
via a fine bore catheter inserted into the trachea.2
The results of six randomized controlled trials (RCTs)
comparing LISA to InSurE or MV demonstrated that LISA was
associated with a reduction in MV.4–9 In systematic reviews,
LISA was associated with reduction in duration of MV within
72hours of birth and BPD (defined as an oxygen requirement
at 36weeks)10,11 and a reduction in the composite outcome of
death or BPD at 36 weeks compared with InSurE.2 No single
study, however, reported a reduction in BPD.
A recent surveydemonstrated that LISA is infrequentlyused
in UK neonatal units and very rarely performed in the delivery
suite.12Wehavebeenusing LISA both on theneonatal unit and
in the delivery suite. Our aim was to determine in our center
whether LISAwas associated with reduced rates of BPD or the
need for intubation or lower durations of invasive MV and
hospital stay by comparing the outcomes of infants who had
LISA to matched historical controls.
Materials and Methods
Each infantwhoreceivedLISAwasmatchedretrospectivelywith
two other infants (controls) who required respiratory support.
The infants were compared with a historical cohort born
between June 2015 and July 2018. The infants were matched
bygestational age, birthweight, sex, antenatal steroid exposure,
and whether they were inborn or transferred ex utero. Infants
were identified from a standardized electronic neonatal data-
base (BadgerNet, UK Neonatal Patient Data Management). The
study period was between July 2018 and March 2020. This
project was registered with St George’s University Hospitals
NHS Foundation Trust (SGH) audit department.
LISA was delivered via a LISAcath, a thin straight catheter
that was passed through the vocal cords and into the trachea.
Infants were administered LISA in the delivery suite if they
weremore than or equal to 25weeks of gestation at birth and
stable on CPAP in the delivery suitewith a fraction of inspired
oxygen (FiO2) requirement of more than 0.3 or had an
increased work of breathing. On the neonatal unit, infants
had LISA if they were more than or equal to 25 weeks of
gestation at birth and were less than 72hours of postnatal
age with an FiO2 requirement of more than 0.3, or had an
increased work of breathing (excluding pneumothorax) or
worsening blood gases with a respiratory acidosis (pH<7.2,
partial pressure of carbon dioxide [PCO2]>8.7 kPa).
The dosage of surfactant was aimed to be between100 and
200mg/kg and rounded closest to 120 or 240mg tominimize
vial use. The historical controls were given surfactant and
ventilated if they had FiO2 requirementmore than 0.3, or had
an increasedworkof breathing (excluding pneumothorax) or
worsening blood gases with a respiratory acidosis (pH<7.2,
PCO2>8.7 kPa). No sedationwas given if LISAwas performed
on the delivery suite. Nonpharmacological methods for
analgesia such as swaddling, sucking on a dummy, or sucrose
were used when LISAwas performed on the neonatal unit. If
the baby remained unsettled, then fentanyl was adminis-
tered (0.5–1 µg/kg/dose).
The outcomes were the need for intubation within
72 hours of birth, the durations of invasive and noninvasive
ventilation, the length of hospital stay (LOS) at SGH and
the referring hospital (local hospital), the total LOS, and the
incidence of BPD (oxygen requirement at 36weeks corrected
age). In addition, any side effects such as desaturations less
than 80%, bradycardia less than 100 beats per minute, apnea,
and surfactant reflux were noted. Data were obtained from
the electronic documentation recording system and cross
checked with the medical notes.
Sample Size
BPD incidence historically has been around 50% in infants
born less than 32 weeks of gestation in our center at
St George’s [14]. A sample size of 25 infants in the LISA
group and 50 controls allowed detection of a 50% reduction
in BPD in the LISA group controlled to the controls with 85%
power and a significance level of 0.05.
Analysis
Differences between the two groups were assessed for
statistical significance using the chi-squared test or the
Mann–Whitney U test as appropriate using IBM SPPS statis-
tical software, V.25 (IBM Corporation).
Results
The results of 25 LISA infants were compared with those of
50 controls (►Table 1). Ninety-six percent of the LISA infants
and 98% of the controls had at least one course (two doses) of
antenatal corticosteroids (p¼0.612). All LISA procedures
were performed by the medical team using video laryngo-
scope; 40% of the procedures were performed by the neona-
tal consultant team and 60% by the members of the junior
doctor team. All the infants received caffeine and were
inborn and 36% of infants received LISA in delivery suite.
All infants in the LISA group received surfactant and 78% of
the control group received surfactant (p¼0.015; ►Table 1).
Forty percent of infants received sedation for LISA. Side
effects noted were apnea, desaturations, and bradycardia
in 24% of infants and surfactant reflux was noted in 16% of
infants. Infants who received LISA had significantly lower
rates of BPD and need for intubation and shorter durations of
invasive ventilation (►Table 2).
Discussion
We have demonstrated that prematurely born infants who
received LISA had a lower incidence of BPD compared with
historical controls. The incidence of BPD in the LISA infants of
approximately 30% is similar to the reported meta-
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analyses2,10,11,13 and the BPD incidence in the control group
is similar to previous data from our center.14 A reduction in
BPD has not been demonstrated in individual LISA trials, but
in contrast to the other studies 36% of the infants in our study
were given LISA at delivery. The reduction in BPD is likely to
be due to a combination of reasons that include a
decreasedMV duration, reduced intubation rates, and earlier
administration of surfactant as 36% of infants received
surfactant in delivery suite.
In previous studies, surfactant reflux, acute desaturations,
bradycardia, and/or need for manual ventilation during LISA
were observed in less than 10%4 to more than 30%10 of
LISA/MIST (minimally invasive surfactant therapy) proce-
dures. Side effects noted in our study were similar to
published studies. The dosage of surfactant was aimed to
be between 100 and 200mg/kg and rounded closest to 120 or
240mg to minimize vial use. The avoidance of mechanical
ventilation trial4 used a dose of 100mg/kg, while the non-
intubated surfactant application trial9 used a “whole” vial of
120mg porcine surfactant per infant. In daily routine, a
whole vial policy often resulting in doses of  150mg/kg
has beenwidely adopted.12 In addition, when LISA is done in
the delivery suite, the birth weight has often to be estimated,
which makes a “whole” vial approach pragmatic.
In a recent survey,12 LISAwas performed by consultants in
91.7% of units, registrars or equivalent in 69.4%, and senior
house officer or equivalent in 25%. Only 40% of LISA proce-
dures were performed by the consultant neonatologists in
our center; this may be because video laryngoscopy is
routinely used for all intubations resulting in improved
confidence in the junior doctors.15
Forty percent of infants in our study received sedation for
LISA. Most centers undertake LISA without analgesia.12 Non-
pharmacological methods of analgesia such as positioning,
holding (“facilitated tucking”), and/or sucrose solutions
are used. A variety of drugs have been studied to provide
analgesia/sedation during InSurE or LISA; fentanyl, ketamine,
and propofol were themost frequently used medications. The
results of studies indicate that those drugsmay help to reduce
pain scores but may interfere with spontaneous breathing.16
Chest rigidity has also been reported when fentanyl is used.
Stress and pain in the neonatal period may have long-term
negative effects and should be avoidedwhenever possible, but
drugs used for stress/pain relief also have acute and long-term
side effects. Likelyas a consequence, thepractice of using these
drugsduring LISAvarieswidely.NoRCTshave lookedat theuse
of premedication for LISA.
There are strengths and some limitations to our study.
This is the first single-center study that has demonstrated a
lower incidence of BPD in infants receiving LISA. Comparison
was made to historical controls, but they were matched for
gestational age, birth weight, sex, antenatal corticosteroid
exposure, and whether inborn or transferred ex utero. The
LISA group all received surfactant but only 78% of the
controls received surfactant; we do, however, not feel this
influenced our results as surfactant administrationper sehas
not been shown to reduce the development of BPD.
In conclusion, we have demonstrated that LISA given in a
single center either in the delivery suite or the neonatal unit
was associated with a reduction in BPD.
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Gender (male) 19 (76%) 38 (76%) 1
Antenatal
corticosteroids
24 (96%) 49 (98%) 0.612
Surfactant 25 (100%) 39 (78%) 0.015
Abbreviations: BW, birth weight; GA, gestational age; LISA, less invasive
surfactant administration.
Data displayed as median (range) or %.



























LOS at SGH (d) 34 (7–259) 62
(7–221)
0.085
Overall LOS (d) 76 (24–259) 85
(27–221)
0.238
BPD 9 (36%) 32 (64%) 0.022
Abbreviations: BPD, bronchopulmonary dysplasia; LISA, less invasive
surfactant administration; LOS, length of hospital stay; NIV, noninvasive
ventilation; SGH, St George’s University Hospitals NHS Foundation Trust.
Data displayed as median (range) or %.
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